To evaluate CD58’s potential in predicting immunotherapy response, we analyzed its correlations with tumor mutational burden (TMB) (Figure 4C) and microsatellite instability (MSI) (Figure 4D) across multiple cancers. This evidence concerns the gene CD58 and neoplasm.